Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.SomaLogic and Novartis have entered a multi-year research agreement to drive Novartis' drug discovery and development using SomaLogic's proteomics technology.
Subscribe to our email newsletter
The proteomic technology will be applied to biomarker discovery, target discovery and validation, and companion diagnostics.
SomaLogic CEO Larry Gold said their technology would help address the issues in drug discovery and development currently faced by biopharmaceutical companies.
The terms of the deal, however, have not been disclosed.